Samina Khan
No más puestos en curso
Fortuna: 7 M $ al 30/09/2023
Perfil
En la actualidad, Samina Khan ocupa el cargo de directora médica y vicepresidenta senior de Reata Pharmaceuticals, Inc. Anteriormente, la Dra. Khan fue Vicepresidenta de Programas Cardio-Renales en Quark Pharmaceuticals, Inc.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 16/05/2023 | 39 491 ( 0.12% ) | 7 M $ | 30/09/2023 |
Antiguos cargos conocidos de Samina Khan.
| Empresas | Cargo | Fin |
|---|---|---|
| REATA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 26/09/2023 |
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | 01/04/2017 |
| Tufts University School of Medicine | Corporate Officer/Principal | - |
Formación de Samina Khan.
| Brandeis University | Masters Business Admin |
| Harvard Medical School | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 2 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Samina Khan
